Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy

The possible interference of tamoxifen with anti-tumor vaccines was studied in a translational view of combined preventive approaches. Tamoxifen treatment of HER-2/neu transgenic mice combined to anti-HER-2/neu cell vaccine did not hamper the efficacy of cancer immunoprevention, and caused a significantly increased production of interferon-γ. These data suggest that tamoxifen could even have a positive impact on the efficacy of cancer immunoprevention.